Table 1.

This Table Displays the Preliminary Dose–Response Comparisons of Each Dose Against Each Other

Dose	Control	10 ng/mL	100 ng/mL	500 ng/mL	1 μg/mL	5 μg/mL	10 μg/mL	50 μg/mL
Control	—	—	—	—	—	—	—	—
10 ng/mL	0.33, 1.00	—	—	—	—	—	—	—
100 ng/mL	0.00, 1.00	0.37, 1.00	—	—	—	—	—	—
500 ng/mL	2.9, 0.26	1.4, 0.71	2.9, 0.26	—	—	—	—	—
1 μg/mL	4.6, 0.10	2.7, 0.31	4.6, 0.10	0.2, 1.00	—	—	—	—
5 μg/mL	28.7, <0.001	25.1, <0.001	28.7, <0.001	12.2, <0.001	13.4, <0.001	—	—	—
10 μg/mL	15.2, <0.001	12.3, <0.001	15.2, <0.001	6.4, 0.03	4.14, 0.126	2.8, 0.28	—	—
50 μg/mL	17.6, <0.001	14.5, <0.001	17.6, <0.001	8.24, 0.01	5.7, 0.61	1.6, 0.61	0.15, 1.00	—

Pearson's chi-square test for goodness of fit with Bonferroni adjustments was performed to compare a given dose with other doses given in the dose escalation preliminary study. The optimal dose was determined by 5 μg/mL as this dose showed significant perforation closure over lower doses, with higher doses not showing any significant difference. Bold highlights those comparisons showing a significant difference between doses in terms of efficacy.